
Carisma Therapeutics Reports Q3 2024 Results, Advances Clinical Programs
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced its financial results for the third quarter of 2024, alongside significant progress in its clinical and preclinical programs. The company …
Carisma Therapeutics Reports Q3 2024 Results, Advances Clinical Programs Read More